Juno's Hans Bishop will take home $287M after Celgene acquired his company. Source: BioSpace

A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31. Source: BioSpace

Companies including Sanofi, J&J, Nestle have dropped out. Source: BioSpace

A look at three small biotech companies that appear to be leading the CRISPR race. Source: BioSpace

A look at three biotech companies that face make-or-break catalysts this year. Source: BioSpace

Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements. Source: BioSpace

EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints. Source: BioSpace

Sometimes the biggest are also the best. That's the case for biotherapeutics stocks. Source: BioSpace

Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace

This Phase 2 trial is a 52-week study evaluating the safety and efficacy of ublituximab at accelerated infusion times as fast as one hour. Source: BioSpace